LUPIN

November 20, 2012

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards launch of Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States, which are the AB rated generic equivalent of Abbott's TRICOR® tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia.

This may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: a/a

Press Release

LUPIN

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin launches Generic TRICOR® Tablets

Mumbai, Baltimore, November 20, 2012: Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).

Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's TRICOR® tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott's TRICOR® Tablets, 48 mg and 145 mg had sales of USD 1.26 billion as per IMS Health, June, 2012.

Commenting on the approval, Ms. Vinita Gupta, CEO, Lupin Pharmaceuticals Inc. & Group President, Lupin Limited said, "We are very happy to bring this product to market in the United States. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price".

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2012, Lupin's Consolidated Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs.8,676 million (USD 182 million) respectively. Please visit http://www.lupinworld.com for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com or

Rajiv Pillai
Head – Investor Relations
Lupin Limited:
Ph: +91 98 20 552 083
Email: rajivpillai@lupinpharma.com

Safe Harbor Statement

**Tricor® is a registered trademark of Abbott Laboratories*